BMO Capital Maintains Outperform on Biogen, Lowers Price Target to $230

Benzinga · 10/17 13:53
BMO Capital analyst Evan Seigerman maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $230.